Abstract
The development of head and neck cancer (HNC) is strongly influenced by the host immune system. Recent evidence for the presence of functional defects and for apoptosis of tumor-infiltrating as well as circulating T cells in patients with HNC emphasizes the fact that their antitumor responses are compromised. It appears that H&N tumors not only effectively escape from the host immune system but also actively corrupt the host antitumor response via several distinct mechanisms. Strategies for restoring immune competence of patients with HNC and for preventing tumor escape are necessary for more effective control of tumor progression. New immunotherapeutic approaches include cytokine-based and DC-based vaccines which are aimed at the restoration of tumor-specific responses and at the protection of immune cells from tumor-induced apoptosis.
Similar content being viewed by others
References
Califano J, van der Reit P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: A genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56: 2488–2492, 1996
Nawroz H, van der Reit P, Hruban RH, Roch W, Ruppert JM, Sidransky D: Allelotype of head and neck squamous cell carcinoma. Cancer Res 54: 1152–1155, 1994
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition; molecular mechanisms and functional significance. Adv Immunol 74: 181–273, 2000
Atarashi Y, Stanson J, Rabinowich H, Sato S, Whiteside TL: Resistance of tumor cells to Fas-mediated apoptosis in head and neck cancer. AACR Proc 41: 557, 2000
Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MRI: Mechanisms of immune suppression in patients with head and neck cancer: Presence of immune suppressive CD34+ cells in cancers that secrete granulocyte-macrophage colony stimulating factor. Clin Cancer Res 1: 95–103, 1995
Whiteside TL: Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: Implications for immunotherapy. Vaccine 20: A46–A51, 2002
Hoffmann TK, Dworacki G, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8: 2553–2562, 2002
Campoli M, Chang C-C, Ferrone S: HLA class I antigen loss, tumor escape and immune selection. Vaccine 20: A40–A45, 2002
Whiteside TL: Tumor-Infiltrating Lymphocytes in Human Malignancies. RG Landes
Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT: Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124: 641–646, 1998
Whiteside TL: Tumor-infiltrating lymphocytes in head and neck cancer. In: Chang AE, Shu S, Landes RG (eds) Immunotherapy of Cancer with Sensitized T Lymphocytes. Austin, TX, 1994, pp. 133–154
Reichert TE, Rabinowich H, Johnson JT, Whiteside TL: Human immune cells in the tumor microenvironment: Mechanisms responsible for signaling and functional defects. J Immunother 21: 295–306, 1998
Reichert TE, Day R, Wagner EM, Whiteside TL: Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58: 5344–5347, 1998
Young MRI, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM: Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer. Int J Cancer 67: 333–338, 1996
Whiteside TL: Down-regulation of ζ chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol Immunother 53: 865–878, 2004
Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL: The number of intratumoral dendritic cells and ζ -chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91: 2136–2147, 2001
Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL: Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 5: 1263–1273, 1999
Kuss I, Donnenberg A, Gooding W, Whiteside TL: Effector CD8+CD45RO-CD27- T cells have signaling defects in patients with head and neck cancer. Br J Cancer 88: 223–230, 2003
Tsukishiro T, Donnenberg AD, Whiteside TL: Rapid turnover of the CD8+CD28-T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 52: 599–607, 2003
Albers AE, Tsukishiro T, Ferris RL, Whiteside TL, DeLeo AB: TCRVβ -restricted T lymphocytes are sensitive to apoptosis in patients with squamous cell carcinoma of the head and neck. Submitted manuscript, 2004
Hoffman TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann F, Myers EN, Appella E, DeLeo AB, Whiteside TL: Frequencies of tetramer+ T cells specific for the wild-type sequence p53264 − 272 peptide in the circulations of patients with head and neck cancer. Cancer Res 62: 3521–3529, 2002
Albers A, Schaefer C, Ferris RL, Kirkwood JM, DeLeo AB, Whiteside TL: Spontaneous apoptosis of tumor-specific tetramer+CD8+ T lymphocytes in the peripheral circulation of patients with cancer. Submitted manuscript, 2004
Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 3755–3762, 2004
Whiteside TL, Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immuno Immunother 46: 175–184, 1998
Gastman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whtieside TL: Fas ligand is expressed onhuman squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res 59: 5356–5364, 1999
Atarashi Y, Kanaya H, Whiteside TL: A modified JAM assay detects apoptosis induced in activated lymphocytes by FasL+ human adherent tumor cells. J Immunol Methods 233: 179–182, 1999
Sato T, Irie S, Kitada S, Reed JC: FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 268: 411–415, 1995
Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J: Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with down-regualtion of its pro apoptotic activity and loss of liver toxicity. J Exp Med 187: 1205–1213, 1998
Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL: Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8: 3137–3145, 2002
Kim J-W, Tsukishiro T, Johnson JT, Whiteside TL: Expression of pro- and anti-apoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck (SCCHN). Clin Cancer Res 10: 5101–5110, 2004
Wieckowski EU, Kim J-W, Stanson JD, Taylor DD, Reichert TE, Whiteside TL: FasL+ and FasL- microvesicles in the circulation of patients with cancer induce apoptosis of activated T lymphocytes. AACR Proc Abst 24, 116, 2004
Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL: Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60: 3542–3549, 2000
Salusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. J Exp Med 179: 1109–1118, 1994
Asai T, Storkus WJ, Whiteside TL: Evaluation of the modified ELISPOT assay for interferon-γ production in monitoring of cancer patients receiving antitumor vaccines. CDLI 7: 145–154, 2000
Cohen EP: Cancer therapy with DNA-based vaccines. Immunol Lett 74: 59–65, 2000
Whiteside TL, Gambotto A, Albers A, Stanson J, Cohen EP: Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo. PNAS 99: 9415–9420, 2002
Artusio E, Hathaway B, Whiteside TL: Transfection of human monocyte-derived dendritic cells with native tumor DNA induces antigen-specific T cell responses in vitro. Submitted Manuscript, 2004
Balz V, Scheckenbach K, Gotte K, Bockmuhl V, Petersen I, Bier H: Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2–11 and human papilloma virus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63: 1188–1191, 2003
Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB: p53110 − 124-specific human CD4+ T-helper cells enhance in vitro generation and anti-tumor function of tumor-reactive CD8+ T-cells. Cancer Res 63: 3675–3681, 2003
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Whiteside, T.L. Immunobiology of head and neck cancer. Cancer Metastasis Rev 24, 95–105 (2005). https://doi.org/10.1007/s10555-005-5050-6
Issue Date:
DOI: https://doi.org/10.1007/s10555-005-5050-6